Building upon its existing pharmaceutical CRO/CDMO operations, BioKey (Cayman), Inc. seeks to strengthen its life sciences platform through strategic partnerships, business development initiatives, and potential acquisitions. The Company may evaluate opportunities involving pharmaceutical development, contract manufacturing, biotechnology, nutraceuticals, and other complementary life sciences businesses. These initiatives are intended to expand operational capabilities, enhance business synergies, and support long-term growth. Any potential acquisition would be subject to due diligence, applicable corporate and regulatory approvals, and the negotiation of definitive agreements. There can be no assurance that any potential transaction will be completed.